Skip to main content
A women caring for several children

“Counting Care In” with Riane Eisler and Gus Speth [Webinar]

Gus Speth

Gus Speth

Co-chair of The Next System Project more

Riane Eisler

Riane Eisler

Author, consultant, and President of the Center for Partnership Studies more

Health & Wellbeing Gender & Sexuality

Measuring the real value of care is the cornerstone of the systemic changes needed to address the unfolding crises in our economic, political, and social world. Find out why on April 14, as The Caring Economy Campaign’s Riane Eisler and The Next System Project’s Gus Speth join together to present the free webinar “Counting Care In.”

Thursday, April 14, 2016
11am Pacific Time
REGISTER HERE

Join us in April and learn:

  • How Social Wealth Economic Indicators (SWEIs) can help build a strong economy that values and invests in the essential work of care
  • How SWEIs provide the evidence-base you need to make the case for caring policies such as paid parental and sick leave, caregiver tax credits, better pay for care workers and educators, and increased investment in early childhood care and education
  • How the SWEIs raise awareness around gender and care that make it essential to explicitly make those foundational dynamics visible.
Gus Speth

Gus Speth

Co-chair of The Next System Project more

Riane Eisler

Riane Eisler

Author, consultant, and President of the Center for Partnership Studies more

More related work

Lower drug prices now

Lower drug costs now through a pharmaceutical public option

House Speaker Nancy Pelosi on September 19 released the “Lower Drug Costs Now Act” (H.R. 3), which would institute a series of measure read more
Prescription drug costs image by TaxRebate.org.uk via Flickr

The Case for a Public Option for the Drug Industry

Under siege from thousands of lawsuits from federal, state, and local governments for its role in the deadly opioid addiction crisis, drug manufacturer Purdue Pharma reached read more
Pharmaceutical products on shelves

Medicine For All: The Case for a Public Option in the Pharmaceutical Industry

Democratic, public ownership of pharmaceutical development, production, and distribution in the U.S. is necessary to combat the increasingly harmful impacts of Big Pharma which decades of regulation have failed to counteract. read more